It is well known that if growth and survival of a tumor depends on estrogen and, therefore, an intact, functional estrogen-dependent signaling pathway, then endocrine therapies such as tamoxifen and aromatase inhibitors are most likely to be of benefit to the breast cancer patient [34]. This evidence concerns the gene CYP19A1 and breast cancer.